The SARS‐CoV‐2 infection cycle is a multistage process that relies on functional
interactions between the host and the pathogen. Here, we repurposed antiviral drugs …

Taking advantage of the uniquely constricted active site of SARS-CoV-2 Nsp14
methyltransferase, we have designed bisubstrate inhibitors interacting with the SAM and …

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the COVID-19
respiratory disease pandemic utilizes unique 2′-o-methyltransferase (2′-O-MTase) …

There are currently no antiviral therapies specific for SARS-CoV-2, the virus responsible for
the global pandemic disease COVID-19. To facilitate structure-based drug design, we …

The COVID-19 pandemic has presented itself as one of the most critical public health
challenges of the century, with SARS-CoV-2 being the third member of the Coronaviridae …

Understanding the molecular basis of innate immune evasion by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is an important consideration for designing the next …

The COVID-19 pandemic reveals the urgent need to develop new therapeutics targeting the
SARS-CoV-2 replication machinery. The first antiviral drugs were nucleoside analogues …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses mRNA capping to
evade the human immune system. The cap formation is performed by the SARS-CoV-2 …

Methylation of the mRNA 5′ cap by cellular methyltransferases enables efficient translation
and avoids recognition by innate immune factors. Coronaviruses encode viral 2′‐O …

ABSTRACT SARS-CoV-2 has caused a global pandemic with significant humanity and
economic loss since 2020. Currently, only limited options are available to treat SARS-CoV-2 …